PRESENTATION VIFOR PHARMA INVESTOR PRESENTATION. August 2018
|
|
- Madeline Summers
- 5 years ago
- Views:
Transcription
1 PRESENTATION VIFOR PHARMA INVESTOR PRESENTATION August 2018
2 VIFOR PHARMA VISION Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies. August
3 AGENDA 1 Experienced leadership team 2 3 Proven track record Leading portfolio in target disease areas Three mid-term strategic growth drivers Investments H performance and 2018 outlook August
4 1 EXPERIENCED LEADERSHIP TEAM Etienne Jornod Executive Chairman Stefan Schulze President and COO Colin Bond Chief Financial Officer Christoph Springer Chief Strategy Officer Dario Eklund Chief Commercial Officer Scott Garland President, Relypsa David Bevan CEO, VFMCRP 1) and Chief Marketing Officer Michael Puri Chief Human Resources Officer 1) Vifor Fresenius Medical Care Renal Pharma August
5 2 PROVEN TRACK RECORD CORPORATE TIMELINE AND STRATEGY 2000 BUILDING IRON PORTFOLIO AND INTERNATIONAL EXPANSION 2000: Venofer US FDA approval 2007: Launch of Ferinject 2008: Acquisition Aspreva 2008: Creation of EU affiliates 2009: Acquisition OM Pharma 2010 BECOMING GLOBAL LEADER IN IRON DEFICIENCY AND ENTERING INTO NEPHROLOGY 2010: Creation of VFMCRP 2013: Injectafer FDA approval 2013: Launch of Velphoro BECOMING GLOBAL LEADER IN NEPHROLOGY AND ENTERING CARDIO-RENAL DISEASE AREA 2015: Mircera License 2015: Veltassa License 2016: Four Licensing Deals 2016: Relypsa Acquisition 2017: Galenica Santé IPO 2017: Vadadustat License 2017: Veltassa EU approval 2017: Mircera license expansion 2018: CR845 License August
6 3 LEADING PORTFOLIO IN TARGET DISEASE AREAS IRON DEFICIENCY NEPHROLOGY CARDIO-RENAL Own Products In-licensed Products 1) Avacopan 1) CCX140 1) Vadadustat 1) CR845 1) 1) Pre-commercial products August
7 4 THREE MID-TERM STRATEGIC GROWTH DRIVERS Ferinject Exploit the Potential through Market Awareness Vifor Fresenius Medical Care Renal Pharma Grow and Enhance Value Veltassa Build a Blockbuster August
8 4 FERINJECT SIGNIFICANT MARKET OPPORTUNITY REMAINS 1) MAT Ferinject In-Market Volume Growth MAT Ferinject Volume Per Capita 2) Launch Date 3% Switzerland % Australia % New Zealand % Sweden % Germany % Turkey % Spain % France % UK % Italy % US ) Based on Quarterly IQVIA MIDAS TM panel, GERS, Insight Health, Q ) 100 mg eq./1 000 population August
9 4 FERINJECT A BLOCKBUSTER BY 2020 FERINJECT IN-MARKET SALES 1) (MCHF) Global i.v. iron market totalled CHF 1,564 million in 2017, growth of 12.7% vs Ferinject responsible for 90.3% of the total value growth of the i.v. iron market in 2017 The market share of Ferinject in value was 50.6% in December 2017 in the top 10 markets Approval in EU / CH First launch in Germany Launch in CH, UK, Spain FAIR-HF study (cardio) FERGI-COR study (gastro) PREFER study (fatigue) New EU guidelines: nephro, cardio, gastro, onco FIND-CKD study (ND- CKD) Injectafer approved in the USA CONFIRM- HF study (cardio) New EU onco guidelines New ESC guidelines (cardio) EFFECT-HF study (cardio) Intensifying promotional effort by Daiichi Sankyo New EU onco guidelines Europe US ROW 1) Based on Quarterly IQVIA MIDAS TM panel, GERS, Insight Health, DLI, data at constant exchange rate (average 2017) August
10 4 FERINJECT THE BLOCKBUSTER PLAN 1 Therapeutic Heart Failure 3 Strong areas with high Gastroenterology partnerships unmet need Nephrology Patient Blood Management Partnering with leading companies in and outside of Europe 2 Geographic Japan (2019) 4 Life Cycle expansion China (2021) Management Key pharmerging markets AFFIRM-AHF HEART-FID August
11 4 VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA THE RATIONALE STRONG IRON AND PHARMA EXPERTISE 55% Stake CR845 1) Avacopan 1) CCX140 1) Vadadustat 1) GLOBAL LEADER IN DIALYSIS 45% Stake 1) Pre-commercial products August
12 4 VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA CURRENT PORTFOLIO ANAEMIA MANAGEMENT MINERAL & BONE MANAGEMENT KIDNEY PROTECTION CKD-ASSOCIATED COMPLICATIONS CARDIO-RENAL MANAGEMENT Avacopan 1) CR845 1) CCX140 1) 1) Vadadustat 1) 1) Pre-commercial products August
13 4 VELTASSA OVERVIEW OF KEY FEATURES Mode of action Calcium-based, non-absorbed High safety profile Limited undesirable effects 52-weeks data AMETHYST-DN study RAASi enabling Included in SmPC 1) in Europe Broad use Acute & Chronic Room temperature storage US: 3 months / EU: 6 months 1) SmPC = summary of product characteristics August
14 AMI patients with in-hospital events (%) 4 VELTASSA ADDRESSES LIFE THREATENING UNMET MEDICAL NEED MORTALITY AND CARDIAC ARREST IN IN-HOSPITAL EVENTS VS SERUM K + DISEASE BACKGROUND 60 Hypokalemia Normal Hyperkalemia Prevalent in CKD and CHF patients Death Asymptomatic Inhibits use of renin angiotensin aldosterone inhibitors (RAASi) Post admission serum potassium level (mean, meq/l) Disease awareness is underdeveloped August
15 Demand (boxes) per BD 4 VELTASSA TOTAL US DEMAND PER BUSINESS DAY (BD) Demand growth: +81% year over year Global net sales: CHF 36.8 million (+51.8%) in H % of lives covered, Medicare coverage increased to 64% Amber study expected to be completed in 2018 August
16 5 R&D INVESTMENTS MILESTONE 2020 STRATEGIC PLAN PHASE 1 PHASE 2 PHASE 3 COMMERCIAL PHASE 4 Own Products Ferroportin inhibitor 1) Anti-infectives AFFIRM-AHF Paediatric AMBER DIAMOND In-licensed Products 2019 CCX140 Avacopan Vadadustat 3) CR ) 1) Iron overload; leveraging iron metabolism expertise 2) Earlier launch possible due to EMA conditional marketing approval 3) Filing expected by the end of 2019 August
17 6 P&L OVERVIEW (IN CHF MILLION) STRONG H RESULTS H H % vs. H Net Sales % Other Income % Gross Profit % EBITDA % Depreciation and amortization % EBIT % Financial result N/A Income tax N/A Net Profit before minorities 1, N/A Net Profit after minorities 1, N/A Core earnings 1 per share N/A Net sales increase of +23.4% driven by Ferinject, Veltassa and Mircera EBITDA increase of +44.5% driven by top-line growth Financial result of CHF 41.8 million, driven by FX gains on intercompany loan repayment Cash taxes fully offset by deferred tax asset recognition 1) Reported earnings after minorities adjusted for amortisation of intangible assets and goodwill of CHF 54.5 million August
18 6 NET SALES 1) (IN CHF MILLION) H H Growth in H Ferinject % Venofer % Mircera % Velphoro % -3.5 Veltassa Others % +9.7% Net Sales % 1) H net sales restated in accordance to IFRS 15 August
19 6 BALANCE SHEET OVERVIEW (IN CHF MILLION) STRONG EQUITY RATIO OF 80.0% NET DEBT OF CHF MILLION EQUITY RATIO OF 80.0% 4, , Cash and cash equivalents Receivables and other Inventories Property a equipment 4, , Current financial liabilities Other current liabilities Long-term liabilities 2, ,710.3 Goodwill and intangibles 3, ,312.9 Shareholders equity August
20 6 CASH FLOW OVERVIEW (IN CHF MILLION) NET DEBT OF CHF MILLION 2018 Opening Cash, 1 January Cash flow from operating activities 38.4 Capex Investing activities, in-licensing, milestones Investments in financial assets and others Cash flow from investing activities Dividend 2017 paid in May Dividend to FMC Proceeds from financial liabilities Repayment of financial liabilities and others Cash flow from financing activities Exchange rate effects 0.5 Increase/(decrease) in cash and cash equivalents Ending cash and cash equivalents, 30 June Liquidity as at 30 June 2018: 31 Dec Jun 2018 Cash & cash equivalents Financial liabilities Net Cash / (Net Debt) CHF million private placements repaid in March Dividend payments to public shareholders CHF million and to FMC CHF million CHF million drawn under CHF 300 million credit facility August
21 6 GUIDANCE 2018 NET SALES AND EBITDA GUIDANCE INCREASED In 2018 at constant exchange rates Vifor Pharma net sales are expected to grow by more than 15% and reported EBITDA by more than 25%. In 2020 net sales are expected to exceed CHF 2 billion and EBITDA to reach a high triple-digit level. For 2018 and 2019, the dividend is expected to be at the same level as for From 2020 onwards, the payout ratio is targeted at 35% of net income. August
22 6 OUTLOOK 2018 PRODUCT LAUNCHES Veltassa commercial launch in key European countries Avacopan approval in Europe late 2018/early 2019 PARTNERING Veltassa partnering in Japan Partnering the Japanese rights for CCX 140 IN-LICENSING Completion of one additional in-licensing deal during the course of 2018 CLINICAL Veltassa : completion of the AMBER study for treatment of patients with resistant hypertension Veltassa : initiation of the DIAMOND outcome study for RAASi enabling Ferroportin inhibitor: completion of phase-i study August
23 CONTACT INFORMATION Colin Bond CFO Phone: Investor Relations Julien Vignot Head Investor Relations Phone: August
24 DISCLAIMER Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company s or, as appropriate, the Company s directors current expectations and projections about future events. By their nature, forwardlooking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forwardlooking statements, which speak only as of the date of this presentation. August
VIFOR PHARMA IR PRESENTATION
PRESENTATION VIFOR PHARMA IR PRESENTATION May 2018 VIFOR PHARMA VISION Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies. May 2018 2 AGENDA 1 Experienced leadership team 2 3 Proven
More informationPRESENTATION VIFOR PHARMA INVESTOR PRESENTATION. April 2019
PRESENTATION VIFOR PHARMA INVESTOR PRESENTATION VIFOR PHARMA OUR VISION Global leader in iron deficiency, nephrology and cardio-renal therapies. 2 EXPERIENCED LEADERSHIP TEAM PROVEN TRACK RECORD ETIENNE
More informationBoard of Directors launches Milestone 2020 strategy plan: Galenica Group to become Vifor Pharma Group and float Galenica Santé on the stock exchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN. PRESS RELEASE Date Contact Investor Relations: Julien Vignot,
More informationGuidance raised at half-year, continued good performance in H2 led to strong full-year results
ANNUAL REPORT 2017 Annual Report 2017 AT A GLANCE Guidance raised at half-year, continued good performance in H2 led to strong full-year results Net sales CHF 1,342.1 million, up 15.2% on a constant currency
More informationFULL VERSION HALF-YEAR REPORT 2018
FULL VERSION HALF-YEAR REPORT 2018 H1 2018 AT A GLANCE H1 performance above expectations H1 net sales CHF 747.4 million, up 23.4% H1 EBITDA CHF 192.0 million, up 44.5% Guidance raised: at constant exchange
More informationEnglish short version ANNUAL REPORT 2017
English short version ANNUAL REPORT 2017 ANNUAL REPORT 2017 AT A GLANCE Guidance raised at half-year, continued good performance in H2 led to strong full-year results Net sales CHF 1,342.1 million, up
More informationConsolidated interim financial statements 2016
16 Galenica Gruppe Consolidated interim financial statements 2016 of the Galenica Group Consolidated interim financial statements 2016 (in Englisch) Consolidated interim financial statements 2016 of the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Veltassa) Reference Number: CP.CPA.117 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Boston EQUITY RESEARCH Company Report Cara Therapeutics (CARA - $14.70) CARA to Benefit from Important Licensing Agreement CARA recently announced that they
More information1,633m 2013 Revenues 2013 ANNUAL RESULTS. 13 March ,427 Employees in % of Revenues for International in 2013
1,633m 2013 Revenues 2013 ANNUAL RESULTS 13 March 2014 55% of Revenues for International in 2013 20,427 Employees in 2013 Disclaimer This presentation contains forward-looking statements (as defined in
More informationHalf year report 2012 of the Galenica Group
Half year report 2012 of the Galenica Group the galenica group excellence in the healthcare market share Price Share price performance 1995 2012 _change in percentages at the end of the quarter in % 1,600
More informationFULL YEAR 2018 PRESS CONFERENCE FEBRUARY 20, Rice Powell CEO. Copyright
FULL YEAR 2018 PRESS CONFERENCE FEBRUARY 20, 2019 Rice Powell CEO Copyright Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the
More informationAnnual report 2016 of the Galenica Group and Galenica Ltd.
Full Version Annual report 2016 of the Galenica Group and Galenica Ltd. The Galenica Group excellence in the healthcare market 2 Galenica Group Milestones 2016 January February March April Pharmacy network
More informationIpsen 2015 Financial Results
Ipsen 2015 Financial Results 1 March 2016 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking
More informationCreating an Oligopoly in the Treatment of End Stage Renal Disease and the Subsequent Impact on Home Hemodialysis Therapies in the United States
Creating an Oligopoly in the Treatment of End Stage Renal Disease and the Subsequent Impact on Home Hemodialysis Therapies in the United States John D Sullivan, Ph.D. Boston University Agenda History Disease
More informationFY17 Results. IDP Education FY17 Results Presentation
FY17 Results IDP Education FY17 Results Presentation 22 August 2017 Important Notice and Disclaimer Disclaimer Non-IFRS Financial Information The material in this presentation has been prepared by IDP
More information2017 Full Year Results. Tuesday 21 November 2017
2017 Full Year Results Tuesday 21 November 2017 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause
More informationFor personal use only
Click to edit Master text styles IDP Education FY16 Results Presentation Twelve months to 30 June 2016 11 February 2016 Important notice and disclaimer Click Disclaimer to edit Master text styles The material
More informationQ RESULTS. 19 July 2017 HAROLD GODDIJN CEO TACO TITULAER CFO
Q2 2017 RESULTS 19 July 2017 HAROLD GODDIJN CEO TACO TITULAER CFO Our strategy is to build on our leading position in navigation technologies and to provide location content, software, and services to
More informationMedical Affairs Dr. Franklin Maddux, Chief Medical Officer North America Dr. Michael Etter, Chief Medical Officer Asia-Pacific
CAPITAL MARKETS DAY 2017 Medical Affairs Dr. Franklin Maddux, Chief Medical Officer North America Dr. Michael Etter, Chief Medical Officer Asia-Pacific 1 Safe harbor statement The following presentation
More informationHALF YEAR REPORT 2013 of the Galenica Group
HALF YEAR REPORT 2013 of the Galenica Group THE GALENICA GROUP EXCELLENCE IN THE HEALTHCARE MARKET SHARE PRICE Share price performance 1995 2013 _change in percentages at the end of the quarter in % 1,600
More informationOerlikon reports strong operating performance in Q2 2012
Oerlikon reports strong operating performance in Q2 2012 Dr. Michael Buscher, CEO Jürg Fedier, CFO Oerlikon Q2 and H1 Results 2012 August 3, 2012 Agenda 1 Business Update Q2 2012 2 Financials Q2 2012 and
More informationANNUAL REPORT 2013 of the Galenica Group and Galenica Ltd.
ANNUAL REPORT 2013 of the Galenica Group and Galenica Ltd. THE GALENICA GROUP EXCELLENCE IN THE HEALTHCARE MARKET EXCELLENCE IN THE HEALTHCARE MARKET VISUAL CONCEPT _Galenica is a diversified Group active
More informationQ Results. Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018
Q3 2018 Results Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018 Agenda 1. Highlights Q3 2018 2. Market outlook 3. Detailed results review 4. Company outlook 5. Q&A Appendix 1 Business summary
More informationFY 2016 Results. DIASORIN SPA March 8, 2017
FY 2016 Results DIASORIN SPA March 8, 2017 Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in
More information2018 Full Year Results 20 November 2018
2018 Full Year Results 20 November 2018 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause actual
More informationInvestment in Health is investment in wealth: the positive dimension of healthcare K. Panagoulias, Al.President SFEE
Investment in Health is investment in wealth: the positive dimension of healthcare K. Panagoulias, Al.President SFEE Healthworld Conference, October 2017 % Healthcare as % of GDP 14,00% 12,00% 10,00% 11,0%
More informationROADSHOW AMSTERDAM MARCH 27, Copyright
ROADSHOW AMSTERDAM MARCH 27, 2019 Copyright Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as
More informationFORM 6-K. FRESENIUS MEDICAL CARE AG & Co. KGaA (Translation of registrant s name into English)
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 FRESENIUS
More informationFRESENIUS MEDICAL CARE AG & Co. KGaA
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2012
More informationIncrease of profitability
Increase of profitability Dr. Michael Buscher, CEO Jürg Fedier, CFO Oerlikon Q1 Results 2012 April 30, 2012 Agenda 1 Business Update Q1 2012 2 Financials Q1 2012 3 Outlook 4 Appendix Page 2 Increase transparency
More informationIpsen. Half Year 2015 Results. 31 July IPSEN pour nom de la société - 07/04/2011 / page 1
Ipsen Half Year 2015 Results 31 July 2015 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive. Forward-looking
More informationQuarterly Report 3rd Quarter rd Quarter 2012 Fresenius Medical Care
Quarterly Report Q3 Fresenius Medical Care Third Quarter 2012 Overview p. 3 Interim Financial report Financial condition and results of operations p. 7 Liquidity and capital resources p. 21 Balance sheet
More informationCosmo Pharmaceuticals FULL YEAR REPORT
FULL YEAR REPORT 2018 SAFE H ARBOUR This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information currently available to our management.
More informationHALF-YEAR Investor Presentation
HALF-YEAR 2015 Investor Presentation AGENDA 1. Performance Highlights HY2015 2. P&L and B/S Details HY2015 3. Outlook 2015 4. Questions & Answers Investors Presentation - HY2015 August 18, 2015 3 PERFORMANCE
More informationFourth Quarter 2013 Financial Results Conference Call & Webcast April 1, 2014
Fourth Quarter 2013 Financial Results Conference Call & Webcast April 1, 2014 Forward Looking Information & Disclosure Certain of the statements contained in this presentation are "forward-looking information
More informationFinancial results & business update. Quarter and year ended 31 December February 2016
Financial results & business update Quarter and year ended 31 December 2015 11 February 2016 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute
More informationTeva Pharmaceutical Industries Ltd. Q August 2, 2018
Teva Pharmaceutical Industries Ltd. Q2 2018 August 2, 2018 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private
More information17 February 2015 Amsterdam, the Netherlands. TNT announces 4Q & FY14 results, sets Outlook agenda and guidance for
PRESS RELEASE 17 February 2015 Amsterdam, the Netherlands TNT announces 4Q & FY14 results, sets Outlook agenda and guidance for 2018-19 4Q14 results Reported revenues 1,787m (+1.6%), reported operating
More informationFinancial results & business update. Quarter and year ended 31 December February 2017
Financial results & business update Quarter and year ended 31 December 2016 14 February 2017 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute
More informationPHOTOCURE ASA RESULTS FOR FIRST QUARTER MAY Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO
PHOTOCURE ASA RESULTS FOR FIRST QUARTER 2018 23 MAY 2018 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation contains certain forward-looking statements
More information2008 Results and Outlook
VZ Group VZ Holding Ltd Beethovenstrasse 24 CH-8002 Zurich Telephone: +41 44 207 27 27 Fax: +41 44 207 27 28 vermoegenszentrum.ch vzonline.ch 2008 Results and Outlook Aarau Basle Berne Frankfurt Geneva
More information2011 Annual Results. Martin Hirzel, Chief Executive Officer (CEO)
2011 Annual Results Martin Hirzel, Chief Executive Officer (CEO) Independent company since May 13, 2011 Autoneum successfully mastered its first year of independence in 2011 and enjoys the ongoing confidence
More informationAkebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals
FOR IMMEDIATE RELEASE Akebia Therapeutics Files Definitive Proxy Statement in Connection with Proposed Merger with Keryx Biopharmaceuticals Mails Letter to Shareholders Highlighting Accelerated Growth
More informationQuarterly Report 2nd Quarter nd Quarter 2012 Fresenius Medical Care
Quarterly Report Q2 Fresenius Medical Care second Quarter 2012 Overview p. 3 Interim Report of Financial Condition and results of operations Financial condition and results of operations p. 7 Liquidity
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More information1st Quarter Revenue. April 22, 2010
1st Quarter Revenue April 22, 2010 Disclaimer This presentation contains forward looking statements. The use of the words "aim(s)," "expect(s)," "feel(s)," "will," "may," "believe(s)," "anticipate(s)"
More informationMAISONS DU MONDE: FULL-YEAR 2017 RESULTS
PRESS RELEASE MAISONS DU MONDE: FULL-YEAR 2017 RESULTS Very good performance across the board, in line with targets Solid sales growth and profitability Excellent free cash flow generation and strong deleveraging
More informationHUGO BOSS First Nine Months Results 2011
HUGO BOSS First Nine Months Results 2011 Mark Langer (CFO) November 2, 2011 Conference Call, First Nine Months Results 2011 HUGO BOSS November 2, 2011 2 / 30 AGENDA OPERATIONAL HIGHLIGHTS FIRST NINE MONTHS
More informationAnalyst Conference Full-year 2017 results
Analyst Conference Full-year results Kuehne + Nagel International AG 28 February 2018 (CET 14.00) Zurich, Switzerland Forward-looking statements This presentation contains forward-looking statements. Such
More informationCSL Limited Full Year Results 15 August CEO Paul Perreault CFO David Lamont
CSL Limited 2018 Full Year Results 15 August 2018 CEO Paul Perreault CFO David Lamont Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials,
More informationInterim FY 2015 results 6 months ended 31 December February 2015
Interim FY 2015 results 31 December 2014 18 February 2015 Highlights Solid trading result for 1H FY2015; change in accounting policy for acquisition of healthcare practices First half result highlights
More informationFull Year Results 2014/15. Analysts Conference November 4, 2015
Full Year Results 2014/15 Cautionary note Certain statements in this presentation regarding the business of Barry Callebaut are of a forwardlooking nature and are therefore based on management s current
More informationFinancial results & business update. Quarter ended 30 September October 2017
Financial results & business update Quarter ended 30 September 2017 18 October 2017 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationFinancial results & business update. Quarter ended 31 March April 2018
Financial results & business update Quarter ended 31 March 2018 18 April 2018 Disclaimer 3 Any remarks that we may make about future expectations, plans and prospects for the company constitute forward-looking
More informationQ RESULTS. Harold Goddijn CEO Taco Titulaer CFO 16 OCTOBER 2018
Q3 2018 RESULTS Harold Goddijn CEO Taco Titulaer CFO 16 OCTOBER 2018 Operational highlights Groupe PSA selected TomTom s maps, navigation and live services for its next generation infotainment BMW Group
More informationQ1 13 RESULTS. Conference Call
Q1 13 RESULTS Conference Call Highlights MAIN TOPICS Q1 13 Group s revenues growing when compared with Q1 12 (+1.3% at CER; +0.2% at current exchange rate) Strong and boosting revenues of tests ex Vit
More informationAnnual General Meeting 2015
Annual General Meeting 2015 Frankfurt May 19, 2015 Rice Powell Chief Executive Officer and Chairman of the Management Board Rice Powell CEO WELCOME Frankfurt May 19, 2015 Agenda 1. Looking back at the
More informationVeloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides Corporate Update
Corporate Release Copenhagen, Denmark, 24 August 2016 INTERIM REPORT FOR THE PERIOD 1 JANUARY TO 30 JUNE 2016 Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2016 and Provides
More informationPress release. ALTANA 2005: Double-digit growth in sales and net income ALTANA AG. Tenth record year in succession Tenth dividend increase: +16%
Press release ALTANA AG P.O. Box 1244 61282 Bad Homburg v.d.h. Herbert-Quandt-Haus Corporate Communications Am Pilgerrain 15 61352 Bad Homburg v.d.h. Germany P +49 (0) 6172 1712-160 F +49 (0) 6172 1712-158
More informationBankhaus Lampe Deutschland Konferenz. Baden-Baden April 13, 2016
Bankhaus Lampe Deutschland Konferenz Baden-Baden April 13, 2016 Our motivation in numbers FY 2015 Every second we provide a dialysis treatment somewhere on the globe in one of our dialysis clinics. 294,381
More informationAMPLIFON: 2017 THIRD YEAR OF RECORD REVENUES AND EBITDA. NET
AMPLIFON: 2017 THIRD YEAR OF RECORD REVENUES AND EBITDA. NET PROFIT AT HISTORIC HIGHS: MORE THAN 100 MILLION EUROS (+58.1%) RECORD REVENUES AND EBITDA FOR THE THIRD YEAR IN A ROW THANKS TO THE EXCELLENT
More informationAdecco delivers on gross margin improvements and cost cuts
Adecco delivers on gross margin improvements and cost cuts Despite weak topline net profit remains in the black and operating cash flow is robust Q1 HIGHLIGHTS (Q1 2009 versus Q1 2008) Revenues of EUR
More information2015 Half Year Results. August 2015
2015 Half Year Results August 2015 Agenda 1 Philip Rogerson, Chairman: Welcome 2 Brian May, FD: Financial Results 3 Michael Roney, CEO: Business Review 4 Q&A 1 Highlights Good set of results Consistent
More informationFor personal use only
ASX / Media release 14 February 2017 COCHLEAR FINANCIAL RESULTS FOR THE SIX MONTHS ENDED DECEMBER 2016 Positive momentum continues across all markets Net profit of $111.4m, up 19% Cochlear implant units
More informationSHL Telemedicine Q Results 30 May 2012
SHL Telemedicine Q1 2012 Results 30 May 2012 Conference Call, 11.00 am CET - Dial-in numbers : From Europe: +41 (0)91 610 56 00 From UK: +44 (0)203 059 58 62 From Israel: 1 80 921 44 27 Forward Looking
More informationUDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017
UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking
More informationGalapagos reports record revenues and increased profitability in 2010
Regulated information 4 March 2011 Galapagos reports record revenues and increased profitability in 2010 Revenues 136.6 M (+29%) Net profit 4.4 M ( 09: 3.0 M) Operating profit 1.0 M ( 09: 1.7 M) Year end
More informationANNUAL REPORT 2016 JAARVERSLAG GESCHÄFTSBERICHT BILAN DE SOCIÉTÉ RAPPORTO DI GESTIONE MEMORIA ANNUAL
ANNUAL REPORT 2016 JAARVERSLAG GESCHÄFTSBERICHT BILAN DE SOCIÉTÉ RAPPORTO DI GESTIONE MEMORIA ANNUAL Dr. Ulrich Wandel, CFO 27 MARCH 2017 DISCLAIMER. 2 THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE,
More informationQ Conference call October 30, Rice Powell - CEO Mike Brosnan - CFO
Q3 2018 Conference call October 30, 2018 Rice Powell - CEO Mike Brosnan - CFO 1 Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of
More informationFourth Quarter Fiscal Year 2017
Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for
More informationFresenius remains on growth course after 14 straight record years
Press Release Matthias Link Corporate Communications Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany T +49 6172 608-2872 F +49 6172 608-2294 matthias.link@fresenius.com www.fresenius.com
More informationThird-Quarter 2018 Earnings Call
Third-Quarter 2018 Earnings Call October 24, 2018 2016 Vertex Pharmaceuticals Incorporated Agenda Introduction Michael Partridge, Senior Vice President, Investor Relations Business Highlights Jeff Leiden,
More informationTemenos announces very strong start to 2018 with Q1 total software licensing growth of 40%
Temenos announces very strong start to 2018 with Q1 total software licensing growth of 40% GENEVA, Switzerland, 18 April 2018 Temenos Group AG (SIX: TEMN), the banking software company, today reports its
More informationDELIVERING OUR GLOBAL GROWTH STRATEGY HALF YEAR PRESENTATION 2016
DELIVERING OUR GLOBAL GROWTH STRATEGY HALF YEAR PRESENTATION 2016 Dechra Pharmaceuticals PLC Half-Yearly Results Six months ended 31 December 2015 Strong performance in the first half Delivering solid
More information2013 Interim Results. 14 August 2013
2013 Interim Results 14 August 2013 1 This presentation contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives.
More informationTemenos announces very strong Q3 results, full year guidance raised
Temenos announces very strong Q3 results, full year guidance raised GENEVA, Switzerland, 17 October 2018 Temenos AG (SIX: TEMN), the banking software company, today reports its third quarter 2018 results.
More informationFY 2014 Results Presentation. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015
FY 2014 Results Presentation Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015 Disclaimer 1. This presentation may contain certain forward-looking statements, including assumptions,
More informationRENAULT GROUP 2012 FINANCIAL RESULTS
RENAULT GROUP 2012 FINANCIAL RESULTS DISCLAIMER Information contained within this document may contain forward looking statements. Although the Company considers that such information and statements are
More informationInvestor Presentation. August 2007
Investor Presentation August 2007 Forward-Looking Statement This presentation should be considered forward-looking and is subject to various risk factors and uncertainties. For more information on those
More informationPuma Energy : Fourth quarter & full year 2018 results Thursday 28 th March Puma Energy
Puma Energy : Fourth quarter & full year 2018 results Thursday 28 th March 2019 Puma Energy The opportunity for Puma Energy Unique footprint, great people & strong business fundamentals in high potential
More information2006 Interim Results. 9 August 2006
2006 Interim Results 9 August 2006 Agenda Introduction Financial review Review of the business Richard Harvey Group Chief Executive Andrew Moss Group Finance Director Richard Harvey Review of AmerUs Tom
More informationRamsay Health Care Christopher Rex, Managing Director. Australia and New Zealand 7th Annual Investment Conference London 9 March, 2010
Ramsay Health Care Christopher Rex, Managing Director Australia and New Zealand 7th Annual Investment Conference London 9 March, 2010 DISCLAIMER This Presentation has been prepared by Ramsay Health Care
More informationIR Presentation Q2 2008
SHL Telemedicine IR Presentation Q2 2008 Forward looking statements This presentation contains forward-looking statements. These statements relate to future events or our future financial i performance
More informationHelloFresh SE QUARTERLY STATEMENT Q QUARTERLY STATEMENT Q HelloFresh SE
QUARTERLY STATEMENT Q3 2018 HelloFresh SE 1 HELLOFRESH AT A GLANCE Key Figures Key Performance Indicators Group 30- Sept 17 YoY growth 30- Sept 17 YoY growth Active customers (in millions) 1.84 1.28 43.7%
More informationHill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016
Hill-Rom Fourth Quarter 2016 Financial Results November 3, 2016 Forward Looking Statements Certain statements in this presentation contain forward-looking statements, within the meaning of the Private
More informationFirst Half 2016 Performance Summary
First Half 2016 Performance Summary Operational and Financial Highlights - 1H 2016 Strong positive growth for the four main plasma proteins, that jointly with the others, take the revenues of the Bioscience
More informationQ1 report. August 30, Richard Hausmann. Gustaf Salford. President and CEO CFO
Q1 report August 30, 2018 Richard Hausmann President and CEO Gustaf Salford CFO Important information This presentation includes forward-looking statements including, but not limited to, statements relating
More informationFresenius Medical Care achieves revised 2018 targets and accelerates investments for future growth
0 Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com
More informationREUTERS / Vasily Fedosenko REUTERS / Mike Blake THOMSON REUTERS 2018 FIRST-QUARTER RESULTS. May 11, 2018
REUTERS / Vasily Fedosenko REUTERS / Mike Blake THOMSON REUTERS 2018 FIRST-QUARTER RESULTS May 11, 2018 Agenda Welcome / Introduction Frank Golden First Quarter 2018 Highlights F&R Strategic Partnership
More informationGeoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO 27 October Q3 results presentation 2016
Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO 27 October 216 Q3 results presentation 216 Forward looking statements In order to utilize the Safe Harbor provisions of the United States
More informationFY 2016 Results March 2nd, 2017
FY 2016 Results March 2nd, 2017 Definitions & assumptions In this presentation: ForEx stands for Foreign Exchange Rates; Organic stands for effect net of ForEx and hedging derivatives; Q4 stands for fourth
More informationThird Quarter Performance Summary. November 2, 2017
Third Quarter 2017 Performance Summary November 2, 2017 Legal Disclaimer The facts and figures contained in this report that do not refer to historical data are future projections and assumptions. Words
More informationZur Rose Group 2017 Results Analyst & Media Conference
Zur Rose Group 2017 Results Analyst & Media Conference Walter Oberhänsli Marcel Ziwica 21 March 2018 Highlights and Lowlights Zur Rose Group Conference call 23 August 2017 3 Highlights and Lowlights Successful
More informationForward-Looking Statements. Consolidated Financial Results for the 3rd Quarter of Fiscal Year François-Xavier Roger Chief Financial Officer
Consolidated Financial Results for the 3rd Quarter of Fiscal Year 2014 François-Xavier Roger Chief Financial Officer February 5, 2015 Forward-Looking Statements This presentation contains forward-looking
More informationCampofrio Food Group 2010 First Quarter Earnings Call
Campofrio Food Group 2010 First Quarter Earnings Call May 12th, 2010 1 Disclaimer 2 This document has been prepared by Campofrio Food Group exclusively for use during the presentation of financial results
More information1Q Performance Summary
1Q 2015 - Performance Summary Operational and Financial Highlights - 1Q 2015 Net profit up by +6.2% to Euros 128.5 million Income grows by +13.8% (+1.1% cc*) to Euros 908.4 million, driven by sales of
More information3 rd quarter back to growth in September. Robert Jan van de Kraats, CFO. Randstad Holding nv October 31, 2013
3 rd quarter 2013 back to growth in September Robert Jan van de Kraats, CFO Randstad Holding nv disclaimer & definitions Certain statements in this document concern prognoses about the future financial
More informationHALF-YEAR 2018 RESULTS
HALF-YEAR 2018 RESULTS Presentation 25 July 2018 AGENDA Content Page Half-Year 2018 Results 3 Focus of Strategic Initiatives H2 2018 and Beyond 21 Impact of IFRS 16 on Financial Results 24 Appendix 28
More informationFor personal use only
Ramsay Health Care Limited MACQUARIE SECURITIES AUSTRALIA CONFERENCE 2015 6 May 2015 Christopher Rex, Managing Director AGENDA 1. Ramsay Health Care Overview 2. Group Financial Highlights for the six months
More information